Inhibrx Biosciences Inc 2024年度报告

FORM 10-K Commission File Number: 001-42031 INHIBRX BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) (858) 795-4220(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☐No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.Yes☐No☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large Accelerated Filer☐Non-accelerated filer☒ Accelerated filer☐Smaller reporting company☒Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☒ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of itsinternal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered publicaccounting firm that prepared or issued its audit report.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrantincluded in the filing reflect the correction of an error to previously issued financial statements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b).Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).Yes☐No☒ As of June 30, 2024, the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately$169.4 million, based on the closing price of the registrant’s common stock on the Nasdaq Global Market of $14.17 per share. As of February 28, 2025, the registrant had 14,475,904 shares of common stock outstanding. Documents Incorporated By Reference The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain informationrequired in Part III of this Annual Report on Form 10-K is incorporated from the Registrant’s Proxy Statement for the 2025 Annual Meeting ofStockholders to be filed with the Securities and Exchange Commission. INHIBRX BIOSCIENCES, INC.ANNUAL REPORT ON FORM 10-KFor the Year Ended December 31, 2024 TABLE OF CONTENTS Special Note Regarding Forward-Looking Statements 1 Item 1.BusinessItem 1A.Risk FactorsItem 1B.Unresolved Staff CommentsItem 1C.CybersecurityItem 2.PropertiesItem 3.Legal ProceedingsItem 4.Mine Safety Disclosures 8585878787Part II.88Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases ofEquity Securities88Item 6.Reserved89Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations90Item 7A.Quantitative and Qualitative Disclosures About Market Risk103Item 8.Financial Statements and Supplementary Data104Item 9.Changes in and Disagreements With Accountants on Accounting and Financial Disclosure135Item 9A.Controls and Procedures135Item 9B.Other Information136Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections136Part III137Item 10.Directors, Executive Officers and Corporate Governance137Item 11.Executive Compensation137Item 12.Security Ownership of Certain Beneficial Owners and Management and Related StockholderMatters137Item 13.Certain Relationships and Related Transactions, and Director Independence137Item 14.Principal Accountant Fees and Services137Part IV.138Item 15.Exhibits and Financial Statement Schedules138Item 16.Form 10-K Summary140 Signatures140 This Annual Report